medigraphic.com
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2021, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2021; 30 (1)

Aspirin-exacerbated respiratory disease and mast cell dysregulation

Carrasco-Ortega CE, Morales-Ríos JE, Huerta-López JG

Language: Spanish
References: 12
Page: 19-23
PDF size: 153.35 Kb.


ABSTRACT

Aspirin-exacerbated respiratory disease is a syndrome with characteristic chronic progress, where eosinophilic sinonasal disease predominates and diverse manifestations occur. The objective of this study is to describe the physiopathology, diagnostic, and treatment of aspirin-exacerbated respiratory disease in pediatric patients and to highlight the importance of opportune diagnosis and therapy at an early age. Positive results observed in some clinical assays with omalizumab suggest the need to conduct longer duration assays that permit the study of antigens potentially responsible for local synthesis of IgE.


REFERENCES

  1. Arias AM. EREA: La enfermedad respiratoria exacerbada por aspirina. Rev Patol Respir. 2019; 22 (2): 59-65.

  2. Méndez SA, Gutiérrez MJ, Coca PA, Vázquez PM. Enfermedad respiratoria relacionada con aspirina tratada con mepolizumab en un paciente pediátrico. Arch Bronconeumol. 2019; 55 (1): 55-57. https://doi.org/10.1016/j.arbres.2018.04.012.

  3. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al. European position paper on rhinosinusitis and nasal polyps. Rhinology. 2020; 58 (Suppl S29): 1-464. https://doi.org/10.4193/Rhin20.600.

  4. Kennedy DW. Aspirin exacerbated respiratory disease (AERD) treatment revisited. Int Forum Allergy Rhinol. 9 (12): 1399-1400. https://doi.org/10.1002/alr.22496.

  5. Ameratunga R, Randall N, Dalziel S, Anderson BJ. Samter's triad in childhood: a warning for those prescribing NSAIDs. Polaner D, editor. Paediatr Anaesth. 2013; 23 (8): 757-759. https://doi.org/10.1111/pan.12216.

  6. Tuttle KL, Schneider TR, Henrickson SE, Morris D, Abonia JP, Spergel JM et al. Aspirin-exacerbated respiratory disease: not always "adult-onset". J Allergy Clin Immunol Pract. 2016; 4 (4): 756-758. https://doi.org/10.1016/j.jaip.2016.05.016.

  7. Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016; 30 (6): 407-413. https://doi.org/10.2500/ajra.2016.30.4370.

  8. Boyce JA. Aspirin sensitivity: lessons in the regulation (and dysregulation) of mast cell function. J Allergy Clin Immunol. 2019; 144 (4): 875-881. https://doi.org/10.1016/j.jaci.2019.08.022.

  9. Li K, Lee A, Abuzeid W. Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management. Med Sci (Basel). 2019; 7 (3): 45. https://doi.org/10.3390/medsci7030045.

  10. Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E. Aspirin exacerbated respiratory disease: current topics and trends. Respir Med. 2017; 135: 62-75. https://doi.org/10.1016/j.rmed.2018.01.002.

  11. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018; 379 (11): 1060-1070. https://doi.org/10.1056/NEJMra1712125.

  12. Pardue JB, Fleming GM, Otillio JK, Asokan I, Arnold DH. Pediatric acute asthma exacerbations: Evaluation and management from emergency department to intensive care unit. J Asthma. 2016; 53 (6): 607-617. https://doi.org/10.3109/02770903.2015.1067323.




2020     |     www.medigraphic.com